New FDA Approved AI Enhances CBCT Image Quality

Introducing CleaRecon DL A Breakthrough for Interventional Radiology

The CleaRecon DL software is designed to eliminate problematic streak artifacts that often appear in cone-beam computed tomography (CBCT) scans used during interventional radiology procedures. For interventional radiologists, GE HealthCare has unveiled CleaRecon DL, a deep learning software specifically developed to tackle these image-degrading artifacts, which can hamper the quality of CBCT acquisitions.

FDA Clearance and Advanced Deep Learning Technology

Recently cleared by the Food and Drug Administration (FDA), CleaRecon DL effectively removes streak artifacts from CBCT reconstructed images, as stated by GE HealthCare.

Designed to remove streak artifacts from reconstructed cone-beam CT images, the FDA-cleared CleaRecon DL software reportedly bolsters image quality for interventional radiology procedures involving the prostate, liver, endovascular aortic repair, and neuroradiology applications, according to GE HealthCare, the manufacturer of the software. (Image courtesy of GE HealthCare.)

Enhanced Image Clarity for Critical Procedures

By employing sophisticated deep learning algorithms, GE HealthCare states that CleaRecon DL significantly improves image clarity. This enhancement is particularly beneficial for interventional radiology procedures concerning the liver and prostate, as well as for neuroradiology applications and operations involving endovascular aortic repair.

A Leap Forward in Interventional Imaging

Arnaud Marie, General Manager for Interventional Solutions at GE HealthCare, commented on the significance of this development:

"The introduction of CleaRecon DL represents a leap forward in the interventional suite and for the advancement of CBCT. By improving image quality and reducing artifacts, this technology can empower clinicians to perform procedures with greater precision and confidence."